Key Highlights
- USD 5.07 trillion is the market capitalization of Apple (NASDAQ:AAPL), the largest of four, at USD 344.84 on October 16, 2026, up 0.83%. Fiscal fourth quarter guidance is 9% to 11% revenue growth, implying USD 111.7 billion to USD 113.8 billion (own arithmetic).
- 3.0% below its implied 52-week high of USD 553.6 is Microsoft (NASDAQ:MSFT) at USD 536.96, on a USD 3.99 trillion market capitalization. Fiscal fourth quarter revenue rose 18% to USD 90.01 billion, Azure grew 43% and passed USD 100 billion of annual revenue.
- 2.3% below its USD 1,292.65 high is Eli Lilly (NYSE:LLY) at USD 1,262.45, on a USD 1.12 trillion market value at the October 15 close. Second quarter revenue rose 48% to USD 23.0 billion, with volume up 60% and realized prices down 13%.
- 2.5% below its USD 291.40 high is AbbVie (NYSE:ABBV) at USD 284.21, on a USD 502.23 billion market value. A USD 216 million IPR&D charge, USD 0.11 per share, cut 2026 adjusted EPS guidance to USD 13.76 to USD 13.96.
Apple (NASDAQ:AAPL)
The company traded 14,442,575 shares, USD 4.98 billion of turnover and 0.098% of market capitalization (own arithmetic). The 0.4x relative volume implies a full-day average of 36.1 million shares, assuming the ratio uses a full-day base (own arithmetic). The stock gapped up 1.19%, opening at an implied USD 346.06, then fell 0.54% from the open. Because large holders work orders over several sessions, light volume on a retreat shows limited seller conviction, and quiet sessions before earnings are common in mega-caps. No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026. RSI is 62.8. Guidance on the USD 102.5 billion year-earlier base gives USD 111.7 billion to USD 113.8 billion of fiscal fourth quarter revenue, with iPhone growth in the mid-teens, and foreign exchange and supply constraints flagged as headwinds. Results come November 2, 2026 at 4:30 p.m. ET. Trailing P/E was not independently verified, so no earnings multiple is cited. CEO John Ternus and CFO Kevan Parekh present the results.
Microsoft (NASDAQ:MSFT)
The software group fell 0.46% on 4.28 million shares (digits partly unreadable in the table) and 0.2x relative volume, USD 2.30 billion of turnover (own arithmetic). The implied high of USD 553.6 exceeds the USD 549.20 published on October 2, 2026, so a new high was set after that date if the table is accurate. Fiscal fourth quarter revenue of USD 90.01 billion beat USD 87.63 billion, and non-GAAP EPS of USD 4.74 beat USD 4.24. Commercial backlog of USD 678 billion, up 84% and up 25% excluding OpenAI, is reported coverage, not independently confirmed. Free cash flow fell 23.19% because capital spending rose 109.63% to USD 35.80 billion, and fiscal 2027 spending is guided at approximately USD 175 billion, which depreciates into cost of revenue for years. The trailing P/E was 28, and 52 of 55 ratings were Buy or Strong Buy on October 2. The report is due October 28, 2026, and guidance language may move the shares more than reported results. More Personal Computing revenue fell 4% in the June quarter.
Eli Lilly (NYSE:LLY)
The drugmaker rose 3.55% to USD 1,251.61 on October 15, 2026 with no company announcement identified. Health Care Select Sector SPDR Fund (NYSEARCA:XLV) gained 1.86% that day, and Lilly is its largest holding at 15.33%, which points to sector rotation. On October 16 it traded up 0.87% at 0.2x relative volume with RSI at 69.4. Second quarter revenue growth of 48% came from 60% higher volume against 13% lower realized prices, and ex-US prices fell 36% as Mounjaro joined China's national reimbursement list while volume there rose 113%. Mounjaro sold USD 9.9 billion and Zepbound USD 4.9 billion. Lilly submitted orforglipron, an oral GLP-1, for type 2 diabetes in the United States. Non-GAAP EPS of USD 8.38 included USD 3.03 of acquired development charges. Guidance of USD 85.0 billion to USD 87.0 billion of revenue and USD 35.50 to USD 36.50 of EPS puts the shares at 35.1 times the midpoint (own arithmetic). Morgan Stanley set USD 1,430 and Cantor Fitzgerald USD 1,440. Results are due October 29, 2026.
AbbVie (NYSE:ABBV)
The drugmaker rose 0.29% at 0.2x relative volume, with RSI at 70.5, above the 70 overbought line, and shares up 9.0% since September 3 (own arithmetic). The 8-K dated October 5, 2026 disclosed USD 216 million of acquired IPR&D and milestones expense, which lowered third quarter EPS guidance to USD 3.73 to USD 3.77. Acquired IPR&D is expensed at once, so deal costs cut EPS in the quarter they occur. The transaction was not named, and the proposed Apogee Therapeutics (NASDAQ:APGE) acquisition at USD 10.9 billion of equity value had no confirmed completion. Skyrizi and Rinvoq produced USD 8.030 billion, 47.3% of second quarter revenue of USD 16.990 billion (own arithmetic), while Humira fell 35.9%. The forward multiple is 20.5 times (own arithmetic), the annual dividend of USD 6.92 yields 2.4%, and tariff exposure is not disclosed. Morgan Stanley holds USD 310, Bank of America USD 305 and UBS USD 275. Results are due October 30, 2026 before the open. Skyrizi beat placebo in Phase 3 Crohn's disease data reported the week of October 12, and the FDA granted two Breakthrough Therapy Designations on October 8.
Where Things Stand
Apple (NASDAQ:AAPL) leads the largest caps at USD 5.07 trillion, 1.27 times Microsoft, which is 3.56 times Eli Lilly, which is 2.23 times AbbVie (own arithmetic on published market values). The four total USD 10.68 trillion. Lilly is nearest its high at 2.3%, then AbbVie at 2.5% and Microsoft at 3.0%, while Apple's high was not retrieved. Microsoft (NASDAQ:MSFT) faces free cash flow pressure. Eli Lilly (NYSE:LLY) carries a 35.1 times multiple. AbbVie (NYSE:ABBV) has an RSI above 70. Apple reports November 2, after Microsoft on October 28, Lilly on October 29 and AbbVie on October 30, 2026.





_11_13_2026_20_30_45_840725.jpg)
Please wait processing your request...